MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 

Location: Categories / Finance & Investment / Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.
Old Articles: <Older 42341-42350 Newer>
The Motley Fool
July 21, 2010
The Not-So-Dirty Secret Behind P&G's Innovation We talk with Inder Sidhu, senior vice president of strategy and planning for worldwide operations at Cisco about innovations at Procter & Gamble. mark for My Articles 264 similar articles
The Motley Fool
July 21, 2010
David Lee Smith
Is It the End for Tony Hayward? There are two schools of thought regarding the BP executive's staying power. Where do you stand? mark for My Articles 651 similar articles
The Motley Fool
July 21, 2010
Anders Bylund
Why I Love This Buyout It gives ON bigger biceps for wrestling a gaggle of global competitors. mark for My Articles 104 similar articles
The Motley Fool
July 21, 2010
Mac Greer
Cisco's Greatest Opportunity and Greatest Challenge The author talks with Cisco VP Inder Sidhu. mark for My Articles 259 similar articles
The Motley Fool
July 21, 2010
Anders Bylund
What's Wrong With EMC Today? What does a company have to do to earn any respect around these parts? mark for My Articles 326 similar articles
The Motley Fool
July 21, 2010
Anand Chokkavelu
Best Buy: Linn Energy, Chesapeake Energy, or SandRidge Energy? Three stocks enter, one stock leaves. mark for My Articles 213 similar articles
The Motley Fool
July 21, 2010
Alyce Lomax
Is Lululemon a Buy? Stick with asanas; avoid the stock of this company that sells fancy yoga apparel. mark for My Articles 114 similar articles
The Motley Fool
July 21, 2010
Seth Jayson
Show Me the Money, Adobe Systems All cash flow is not created equal. mark for My Articles 454 similar articles
The Motley Fool
July 21, 2010
Tom Gardner
Intel Versus Microsoft Versus Cisco Fool co-founder ranks three tech titans. mark for My Articles 248 similar articles
The Motley Fool
July 21, 2010
Brian Orelli
15% Revenue Growth Is Good for Pfizer, but Not Gilead Gilead needs to reaccelerate growth. mark for My Articles 147 similar articles
<Older 42341-42350 Newer>    Return to current articles.